<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881929</url>
  </required_header>
  <id_info>
    <org_study_id>KN026-208</org_study_id>
    <nct_id>NCT04881929</nct_id>
  </id_info>
  <brief_title>Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer</brief_title>
  <official_title>Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-lable, multicenter, and single arm phase II trial to evaluate treatment with&#xD;
      KN026 plus docetaxel as neoadjuvant therapy in patients with early-stage (T1c or 2, N1, M0;&#xD;
      T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3, N2, M0; T3N1M0; T1c or 2 or 3, N3a or&#xD;
      3b, M0) HER2-positive breast cancer. The subjects will receive KN026 30 mg/kg IV + Docetaxel&#xD;
      75/m2 every 3 weeks for four cycles prior to surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping&#xD;
      epitopes of HER2, leading to a dual HER2 signal blockade.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tp CR as assessed by local pathologist</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>total pathological complete response as assessed by local pathologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bp CR as assessed by local pathologist</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>breast pathological complete response assessed by local pathologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as assessed by the investigator according to RECIST 1.1</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Objective response rate as assessed by the investigator according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety as assessed by the investigator according to RECIST 1.1</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Incidence, type, and severity of adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>KN026 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026</intervention_name>
    <description>KN026 in Combination With Docetaxel</description>
    <arm_group_label>KN026 + Docetaxel</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject &gt;= 18 years;&#xD;
&#xD;
          -  Histologically or cytologically confirmed HER2-positive breast cancer defined as 3+&#xD;
             determined by validated IHC or positive by in situ hybridization (ISH);&#xD;
&#xD;
          -  Early-stage (T1c or 2, N1, M0; T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3,&#xD;
             N2, M0; T3N1M0; T1c or 2 or 3, N3a or 3b, M0) breast cancer;&#xD;
&#xD;
          -  Adequate organ function assessed within 7 days prior to first trial treatment;&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) â‰¥ 55% at baseline;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IV (metastatic) breast cancer;&#xD;
&#xD;
          -  Inflammatory breast cancer;&#xD;
&#xD;
          -  Previous anti-cancer therapy or radiotherapy for any malignancy;&#xD;
&#xD;
          -  Major surgery for any reason within 28 days;&#xD;
&#xD;
          -  History of uncontrolled intercurrent illness;&#xD;
&#xD;
          -  Other medical conditions that at the discretion of investigator interfere with the&#xD;
             requirements of the trial in terms of safety or efficacy evaluation, or treatment&#xD;
             compliance;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benlong Yang, professor</last_name>
    <phone>13764572123</phone>
    <email>yblqhdx@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiong Wu, professor</last_name>
    <phone>13601637369</phone>
    <email>wujiong1122@vip.sina.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

